Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
Zeng W, Zhang Q, Zhu Y, Ou R, Peng L, Wang B, Shen H, Liu Z, Lu L, Zhang P, Liu S.
Zeng W, et al. Among authors: zhang p, zhang q.
Cancer Invest. 2022 Mar;40(3):282-292. doi: 10.1080/07357907.2021.2005798. Epub 2021 Nov 25.
Cancer Invest. 2022.
PMID: 34797742